Integrated Filing — IndAS



General information about company

Scrip Code 544647
NSE Symbol NEPHROPLUS
MSEI Symbol NOTLISTED
ISIN INE428V01029
Name of company Nephrocare Health Services Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 10-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-01-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 10-02-2026   19:30:00
End date and time of board meeting 10-02-2026   20:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 25,972.90 73,323.00
Other income 331.60 1,294.40
Total income 26,304.50 74,617.40
2 Expenses
(a) Cost of materials consumed 5,851.70 16,715.90
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 4,310.30 12,586.10
(e) Finance costs 596.00 5,706.20
(f) Depreciation, depletion and amortisation expense 2,186.10 6,482.20
(f) Other Expenses
1 Healthcare professional fees 3,058.80 8,286.20
2 Hospital fees 2,008.70 5,875.50
3 Other expenses 4,656.90 12,539.80
Total other expenses 9,724.40 26,701.50
Total expenses 22,668.50 68,191.90
3 Total profit before exceptional items and tax 3,636.00 6,425.50
4 Exceptional items 0.00 0.00
5 Total profit before tax 3,636.00 6,425.50
6 Tax expense
7 Current tax 939.40 2,677.90
8 Deferred tax (527.40) (899.40)
9 Total tax expenses 412.00 1,778.50
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,224.00 4,647.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,224.00 4,647.00
17 Other comprehensive income net of taxes 157.40 1,270.70
18 Total Comprehensive Income for the period 3,381.40 5,917.70
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 3,224.00 4,647.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 3,381.40 5,917.70
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 2,006.80 2,006.80
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.43 5.32
Diluted earnings (loss) per share from continuing operations 3.35 5.03
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.43 5.32
Diluted earnings (loss) per share from continuing and discontinued operations 3.35 5.03
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes : 1. The above consolidated financial results of Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited)('the Company') and its subsidiaries (Company and its subsidiaries together referred to as “the Group”) for the quarter and nine months ended 31 December 2025, have been prepared in accordance with the Indian Accounting Standard (referred to as 'Ind AS') 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. 2. These consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10 February 2026. The Statutory auditors of the Company have conducted a 'Limited Review' of the consolidated financial results in accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations') and have issued an unmodified review report thereon. 3. The consolidated financial results include the results of the following entities: Holding Company Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) Subsidiary companies Nephrocare Health Services Central Asia FE LLC Nephrocare Health Services Nepal Private Limited Nehrocare Health Services International Pte Ltd Nephrocare Health Services Saudi Arabia Company Nephro Plus Kidney Services Company Nephrocare Health Care Services, Philippines Inc. Anram Medical Group Inc. Cadiz Dialysis Hub Inc. Dialysis Asia and Patient Care Center Inc. People’s Center For Hemodialysis Care Inc. Curis Hemodialysis Clinic Inc. Mega Health Dialysis Center Inc. Universe Dialysis and Kidney Care Centre Inc. St. Margareth Dialysis and Biocare Centre Inc. Medical Experts Group and Associates Inc. Curis Cavite Renal Corporation Renal Therapy Solutions, Inc. Rizal Dialysis and Wellness Centre OPC Bioregen Hemo Center Inc. Carmona Dialysis System Inc. Infini Care Health Systems Inc. Kolff Dialysis Inc. AIZ Hemodialysis Centre Inc. Nephro Alliance Ventures Inc. 4. The Group is primarily engaged in business of providing dialysis and sale of related healthcare services and products which is considered to be the only reportable segment as per Ind AS 108, 'Operating Segments'. 5.Geographical segment The business of providing dialysis and sale of related healthcare services and products are managed on a worldwide basis. The geographic information analyses the Group’s revenue by the Company’s country of domicile (i.e. India) and outside India. The revenue from operations by geographical location is presented below Geographical segment Quarter Ended Nine months ended Year ended 31 December 2025 30 September 2025 31 December 2024 31 December 2025 31 December 2024 31 March 2025 India 1,478.42 1,450.56 1,302.02 4,321.24 3,783.36 5,155.02 Outside India 1,118.87 1,006.62 670.55 3,011.06 1,582.83 2,403.10 6. The figures for the preceding quarter ended 30 September 2025 and corresponding quarter and nine months ended 31 December 2024, as reported in these consolidated financial results, have been approved by the Company's Board of Directors but have not been audited or reviewed by the statutory auditors. This is pursuant to the requirement of submitting quarterly consolidated financial results becoming applicable to the Company with effect from the quarter ended 31 December 2025 pursuant to the listing of its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE'). The Company's equity shares were listed on the BSE and NSE on 17 December 2025. Hence, this is the first statement of consolidated financial results being prepared and submitted in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended. 7. During the quarter ended 31 December 2025, the Company completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of Rs. 2 each. The issue comprised a fresh issue of 7,689,918 equity shares and an offer for sale of 11,253,102 equity shares. The fresh issue included 7,609,118 equity shares issued at an issue price of Rs. 460 per share and 80,800 equity shares issued to employees of the Company at a discounted issue price of Rs. 419 per share. 8. On 21 November 2025, the Government of India notified the four Labour Codes - The Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour and Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to the changes in regulations. The Company has assessed and accounted the incremental impact of these changes on the basis of actuarial opinion obtained and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 9. During the nine months ended 31 December 2025 and the quarter ended 30 September 2025, the Company incurred interest expense on financial liabilities measured at fair value through profit or loss (FVTPL) aggregating to Rs.371.89 million. The said item is non-cash and non-recurring nature and the impact has been presented under “Finance costs” in the Statement of Consolidated Financial Results. 10. The results for quarter and nine months ended 31 December 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors). *Earnings per equity share is not annualised for the quarters and nine months ended.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gains/(loss) on defined benefit plans (17.20) (4.10)
2 Tax on remeasurement gains/(loss) on defined benefit plans 4.30 1.00
Total Amount of items that will not be reclassified to profit and loss (12.90) (3.10)
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translating financial statements of foreign operations 170.30 1,273.80
Total Amount of items that will be reclassified to profit and loss 170.30 1,273.80
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 157.40 1,270.70





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited
Declaration of unmodified opinion or statement on impact of audit qualification
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto